✉news TechnologyTechnology first seen 2 h ago, last 2 h ago, peak #31
Novartis to buy Abogen for $7.8bn in autoimmune BiTE push
Original: Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal
Novartis has agreed to acquire Chinese biotech Abogen in a deal worth $7.8bn, betting on bispecific T-cell engagers (BiTEs) aimed at autoimmune diseases. The move signals the Swiss drugmaker's push into next-generation immunology therapies, expanding its pipeline beyond traditional treatments. Industry watchers see it as part of a broader wave of big pharma deals targeting autoimmune conditions with engineered antibody technologies.
Why now: The $7.8bn acquisition is a major pharma deal that could reshape Novartis's autoimmune drug pipeline.
Evidence
- Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal · Pharmaceutical Technology
API: https://socialmediatrends-api.osmike.com/v1/trends/735372